Johnson & Johnson (JNJ) reshuffled management and reorganized some units in moves its chief said will improve the health-care giant’s focus on existing businesses while allowing it to explore new market opportunities. The reorganization comes at a time when J&J is cutting costs in response to challenges including a downturn in sales of key products such as the anemia drug Procrit and the Cypher coronary-stent device. Another challenge is various ongoing government investigations into J&J’s sales and marketing practices, part of which played a role in the retirement of the company’s device-unit chief earlier this year.
